Hematological Malignancies

Rationale for immunotherapy of malignant lymphoma

• Long term side effects of chemo- and radiotherapy • Poor prognosis of patients with relapse or refractory disease

• Small amount of malignant cells (Hodgkin) • Residual dormant cells lead to relapse • Good target antigens (CD20, CD30, others) • Lymphoma well vascularized